Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.7 USD | -6.90% | -4.93% | -69.28% |
Financials (USD)
Sales 2024 * | 278M | Sales 2025 * | 372M | Capitalization | 282M |
---|---|---|---|---|---|
Net income 2024 * | -190M | Net income 2025 * | -89M | EV / Sales 2024 * | 1.83 x |
Net Debt 2024 * | 226M | Net Debt 2025 * | 224M | EV / Sales 2025 * | 1.36 x |
P/E ratio 2024 * |
-1.4
x | P/E ratio 2025 * |
-3.05
x | Employees | 597 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.87% |
Latest transcript on Revance Therapeutics, Inc.
1 day | -6.90% | ||
1 week | -4.93% | ||
Current month | -4.93% | ||
1 month | -38.36% | ||
3 months | -56.17% | ||
6 months | -61.92% | ||
Current year | -69.28% |
Managers | Title | Age | Since |
---|---|---|---|
Mark Foley
CEO | Chief Executive Officer | 58 | 17-09-04 |
Tobin Schilke
DFI | Director of Finance/CFO | 49 | 18-11-04 |
Azita Nejad
CTO | Chief Tech/Sci/R&D Officer | - | 13-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Angus Russell
CHM | Chairman | 68 | 11-02-28 |
Mark Foley
CEO | Chief Executive Officer | 58 | 17-09-04 |
Jill Beraud
BRD | Director/Board Member | 63 | 19-06-03 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.18% | 0 M€ | 0.00% | - | |
0.14% | 0 M€ | 0.00% | - | |
0.06% | 415 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-06-07 | 2.7 | -6.90% | 1,280,004 |
24-06-06 | 2.9 | -4.29% | 1,028,766 |
24-06-05 | 3.03 | +4.12% | 1,597,428 |
24-06-04 | 2.91 | -3.32% | 1,381,617 |
24-06-03 | 3.01 | +5.99% | 2,633,469 |
Delayed Quote Nasdaq, June 07, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-69.28% | 282M | |
+0.82% | 91.94B | |
-1.32% | 38.74B | |
-12.88% | 32.82B | |
+64.77% | 26.66B | |
-16.31% | 15.32B | |
-5.78% | 13.3B | |
-11.38% | 11.65B | |
+173.10% | 10.37B | |
-49.84% | 10.12B |
- Stock Market
- Equities
- RVNC Stock